Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of dazodalibep in Sjögren’s syndrome with moderate-to-severe systemic disease activity
2023-503904-10-00Phase 3Completed
- Sponsor
- Horizon Therapeutics
- Start
- Jun 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 27
01
Overview
Phase 3, randomised, double-blind trial in Sjögren's syndrome comparing Dazodalibep with Placebo (2 arms). Primary endpoint: Change from baseline in ESSDAI score at Week 48. Started Jun 2024; status: completed.
02
Drugs
dazodalibep
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on 2023-503904-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503904-10-00.